SUCCESSFUL TREATMENT BY RITUXIMAB OF RHEUMATOID ARTHRITIS RESISTANT TO THE STANDARD SCHEME OF BASIC THERAPY


Cite item

Full Text

Abstract

Among the variety of immune disorders that underlie the development of autoimmune diseases, the examination of defects in cell regulation is of particular interest, especially in the context of the development of new pathogenetically justified approaches to treatment. The use of anti-B-cell preparations, namely the single registered to date preparation of this group - rituximab, is considered as a new method of treatment of rheumatoid arthritis. The case report of successful treatment by rituximab of young patient with severe rheumatoid arthritis resistant to the standard schemes of basic therapy is presented.

References

  1. Насонов Е.Л. Ритуксимаб в лечении ревматических болезней // Научно-практическая ревматология. 2008. Прил. к № 1. С. 3-10.
  2. Каратеев Д.Е. Современная медикаментозная терапия ревматоидного артрита // Лечащий врач. 2007. № 2.
  3. Клинические рекомендации. Ревматология // Под ред. Е.Л. Насонова. М., 2006. 288 с.
  4. Emery P, Suarez-Almazor M. Rheumatoid Arthritis. Clin Evid 2003;10:1454-76.
  5. Салихов И.Г., Мясоутова Л.И., Бадеева М.Ю. и др. Опыт применения ритуксимаба в лечении ревматоидного артрита // Лечащий врач. 2008. № 4. С. 88-90.
  6. Cohen SB, Emery P, Greenwald MW, et al; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54(9):2793-806.
  7. Emery P, Fleishmann R, Filipowicz-Sosnowska A, et al. for the DANCER Study group. The Efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomized, double-blind, placebo-controlled dose-range trial. Arth Rneum 2006;54:1390-400.
  8. Emery Р, Rigby WF, Combe B, et al. Efficacy and Safety of Rituximab (RTX) as first-line biologic therapy in patients with active rheumatoid arthritis: results of a phase III randomized controlled study (SERENA). and ACR 2008, San Francisco, abstr. 364.
  9. Каратеев Д.Е., Лучихина Е.Л., Тогизбаев Г. Современные принципы ведения больных ранним артритом // РМЖ. 2008. № 24. С. 1610.
  10. Rivera A, Chen CC, Ron N, et al. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int Immunol 2001;13:1583-93. doi: 10.1093/intimm/13.12.1583.
  11. Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417-23.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies